232 related articles for article (PubMed ID: 31025931)
1. Present and novel biologic drugs in primary Sjögren's syndrome.
Fasano S; Isenberg DA
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):167-174. PubMed ID: 31025931
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
3. Present and future of biologic drugs in primary Sjögren's syndrome.
Sambataro D; Sambataro G; Dal Bosco Y; Polosa R
Expert Opin Biol Ther; 2017 Jan; 17(1):63-75. PubMed ID: 27616561
[TBL] [Abstract][Full Text] [Related]
4. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapies in primary Sjögren's syndrome.
Bowman SJ
Curr Pharm Biotechnol; 2012 Aug; 13(10):1997-2008. PubMed ID: 22208654
[TBL] [Abstract][Full Text] [Related]
6. Use of Biologics in Sjögren's Syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
[TBL] [Abstract][Full Text] [Related]
7. Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment.
Both T; Dalm VA; van Hagen PM; van Daele PL
Int J Med Sci; 2017; 14(3):191-200. PubMed ID: 28367079
[TBL] [Abstract][Full Text] [Related]
8. SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
Andréu Sánchez JL; Fernández Castro M; Del Campo Fontecha PD; Corominas H; Narváez García FJ; Gómez de Salazar JR; Rua-Figueroa Í; Abad Hernández MÁ; Álvarez Rivas MN; Montes JDP; Francisco Hernández FM; Gantes Pedraza MÁ; Greco Merino MG; Hernández MV; Navarro Compán MV; Solarte JAP; Romero Bueno FI; Park HS; Sivera Mascaró F
Reumatol Clin (Engl Ed); 2019; 15(6):315-326. PubMed ID: 30683506
[TBL] [Abstract][Full Text] [Related]
9. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
10. Biologics in Sjögren's syndrome.
Skarlis C; Marketos N; Mavragani CP
Pharmacol Res; 2019 Sep; 147():104389. PubMed ID: 31415917
[TBL] [Abstract][Full Text] [Related]
11. The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.
Felten R; Scher F; Sibilia J; Gottenberg JE; Arnaud L
Autoimmun Rev; 2019 Jun; 18(6):576-582. PubMed ID: 30959220
[TBL] [Abstract][Full Text] [Related]
12. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.
Wise LM; Arkfeld DG
Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes.
Fasano S; Mauro D; Macaluso F; Xiao F; Zhao Y; Lu L; Guggino G; Ciccia F
Clin Exp Rheumatol; 2020; 38 Suppl 126(4):315-323. PubMed ID: 33095148
[TBL] [Abstract][Full Text] [Related]
15. [Current therapeutic options in Sjögren's syndrome].
Hansen A; Dörner T
Z Rheumatol; 2010 Feb; 69(1):19-24. PubMed ID: 20013285
[TBL] [Abstract][Full Text] [Related]
16. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for primary Sjögren's syndrome.
Gandolfo S; De Vita S
Expert Opin Emerg Drugs; 2019 Jun; 24(2):121-132. PubMed ID: 31286787
[No Abstract] [Full Text] [Related]
18. Treatment of Sjögren's syndrome: current therapy and future directions.
Fox RI; Fox CM; Gottenberg JE; Dörner T
Rheumatology (Oxford); 2021 May; 60(5):2066-2074. PubMed ID: 31034046
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
20. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.
Carsons SE; Vivino FB; Parke A; Carteron N; Sankar V; Brasington R; Brennan MT; Ehlers W; Fox R; Scofield H; Hammitt KM; Birnbaum J; Kassan S; Mandel S
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):517-527. PubMed ID: 27390247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
